A Patient With CKD Develops Cholestatic Liver Injury During a Clinical Trial
Year: 2017
Type: article
Abstract: Patients with chronic kidney disease (CKD) develop disordered phosphate metabolism, characterized by abnormalities in phosphate and fibroblast growth factor 23 (FGF23) levels.1 Higher serum phosphate and FGF23 levels are associated with increased risk of mortality in the CKD population.2,3 Large clinical trials are needed to determine whether lowering phosphate and FGF23 levels will improve clinical outcomes in patients with CKD. There is growing interest in using nicotinamide (NAM) for management of hyperphosphatemia in patients with end-stage renal disease who are undergoing dialysis.
Source: Kidney International Reports
Authors: Emma D.A. Wagener, Nao Souma, Alexander Hodakowski, Carlos Martinez, Patrick Fox, Rupal Mehta, Matthew J. O’Brien, Maureen Bolon, Laura Kulik, Guang-Yu Yang, Tamara Isakova, Geoffrey A. Block, Alfred K. Cheung, Michael F. Flessner, Linda Fried, Jennifer J. Gassman, Joachim H. Ix, John W. Kusek, Dominic Raj, Kalani L. Raphael, Stuart M. Sprague, Myles Wolf
Institution: Northwestern University
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,800
Award: G2886698120
OpenAlex ID: W2767566421